 | • レポートコード：QAF27925 • 出版社/出版日：QYResearch / 2021年3月24日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（即日納品） • 産業分類：医薬品 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本市場調査資料では、世界の水痘弱毒生ワクチン市場について種類別（一価ワクチン、混合ワクチン）、用途別（子供用注射、大人用注射）、地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2016年～2027年までの市場規模と予測（販売量、売上、価格）、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・水痘弱毒生ワクチン市場の概要 ・世界の主要地域別水痘弱毒生ワクチン市場規模2016-2027 ・主要プレイヤーの競争状況・市場シェア ・世界の水痘弱毒生ワクチン市場規模2016-2021：種類別（一価ワクチン、混合ワクチン） ・世界の水痘弱毒生ワクチン市場予測2012-2027：種類別（一価ワクチン、混合ワクチン） ・世界の水痘弱毒生ワクチン市場規模2016-2021：用途別（子供用注射、大人用注射） ・世界の水痘弱毒生ワクチン市場予測2012-2027：用途別（子供用注射、大人用注射） ・水痘弱毒生ワクチンのアメリカ市場規模と予測2016-2021 ・水痘弱毒生ワクチンのヨーロッパ市場規模と予測2016-2021 ・水痘弱毒生ワクチンの中国市場規模と予測2016-2021 ・水痘弱毒生ワクチンの日本市場規模と予測2016-2021 ・水痘弱毒生ワクチンの東南アジア市場規模と予測2016-2021 ・水痘弱毒生ワクチンのインド市場規模と予測2016-2021 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Merck、BCHT、Shanghai Institute、GSK、Keygen、Green Cross、Biken、Shanghai Rongsheng Biotech、Changchun Changsheng Life Sciences Limited） ・水痘弱毒生ワクチンの製造コスト分析 ・販売チャネル、流通業者、顧客 ・水痘弱毒生ワクチンの市場動向・機会・課題 ・調査の結論 |
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
Market Analysis and Insights: Global Varicella Attenuated Live Vaccine Market
The global Varicella Attenuated Live Vaccine market was valued at US$ 2553.6 in 2020 and will reach US$ 3287.4 million by the end of 2027, growing at a CAGR of 4.3% during 2022-2027.
Global Varicella Attenuated Live Vaccine Scope and Market Size
The global Varicella Attenuated Live Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Varicella Attenuated Live Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Monovalent Vaccine
Combination Vaccine
Segment by Application
Kids Injection
Adults Injection
The Varicella Attenuated Live Vaccine market is analysed and market size information is provided by regions (countries). Segment by Application, the Varicella Attenuated Live Vaccine market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
1 Varicella Attenuated Live Vaccine Market Overview
1.1 Varicella Attenuated Live Vaccine Product Scope
1.2 Varicella Attenuated Live Vaccine Segment by Type
1.2.1 Global Varicella Attenuated Live Vaccine Sales by Type (2016 & 2021 & 2027)
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Varicella Attenuated Live Vaccine Segment by Application
1.3.1 Global Varicella Attenuated Live Vaccine Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Varicella Attenuated Live Vaccine Market Estimates and Forecasts (2016-2027)
1.4.1 Global Varicella Attenuated Live Vaccine Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Varicella Attenuated Live Vaccine Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Varicella Attenuated Live Vaccine Price Trends (2016-2027)
2 Varicella Attenuated Live Vaccine Estimates and Forecasts by Region
2.1 Global Varicella Attenuated Live Vaccine Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Varicella Attenuated Live Vaccine Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2016-2021)
2.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2016-2021)
2.3 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Varicella Attenuated Live Vaccine Estimates and Projections (2016-2027)
2.4.2 Europe Varicella Attenuated Live Vaccine Estimates and Projections (2016-2027)
2.4.3 China Varicella Attenuated Live Vaccine Estimates and Projections (2016-2027)
2.4.4 Japan Varicella Attenuated Live Vaccine Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Varicella Attenuated Live Vaccine Estimates and Projections (2016-2027)
2.4.6 India Varicella Attenuated Live Vaccine Estimates and Projections (2016-2027)
3 Global Varicella Attenuated Live Vaccine Competition Landscape by Players
3.1 Global Top Varicella Attenuated Live Vaccine Players by Sales (2016-2021)
3.2 Global Top Varicella Attenuated Live Vaccine Players by Revenue (2016-2021)
3.3 Global Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccine as of 2020)
3.4 Global Varicella Attenuated Live Vaccine Average Price by Company (2016-2021)
3.5 Manufacturers Varicella Attenuated Live Vaccine Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Varicella Attenuated Live Vaccine Market Size by Type
4.1 Global Varicella Attenuated Live Vaccine Historic Market Review by Type (2016-2021)
4.1.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2016-2021)
4.1.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2016-2021)
4.1.3 Global Varicella Attenuated Live Vaccine Price by Type (2016-2021)
4.2 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Varicella Attenuated Live Vaccine Sales Forecast by Type (2022-2027)
4.2.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Type (2022-2027)
4.2.3 Global Varicella Attenuated Live Vaccine Price Forecast by Type (2022-2027)
5 Global Varicella Attenuated Live Vaccine Market Size by Application
5.1 Global Varicella Attenuated Live Vaccine Historic Market Review by Application (2016-2021)
5.1.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2016-2021)
5.1.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2016-2021)
5.1.3 Global Varicella Attenuated Live Vaccine Price by Application (2016-2021)
5.2 Global Varicella Attenuated Live Vaccine Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Varicella Attenuated Live Vaccine Sales Forecast by Application (2022-2027)
5.2.2 Global Varicella Attenuated Live Vaccine Revenue Forecast by Application (2022-2027)
5.2.3 Global Varicella Attenuated Live Vaccine Price Forecast by Application (2022-2027)
6 North America Varicella Attenuated Live Vaccine Market Facts & Figures
6.1 North America Varicella Attenuated Live Vaccine Sales by Company
6.1.1 North America Varicella Attenuated Live Vaccine Sales by Company (2016-2021)
6.1.2 North America Varicella Attenuated Live Vaccine Revenue by Company (2016-2021)
6.2 North America Varicella Attenuated Live Vaccine Sales Breakdown by Type
6.2.1 North America Varicella Attenuated Live Vaccine Sales Breakdown by Type (2016-2021)
6.2.2 North America Varicella Attenuated Live Vaccine Sales Breakdown by Type (2022-2027)
6.3 North America Varicella Attenuated Live Vaccine Sales Breakdown by Application
6.3.1 North America Varicella Attenuated Live Vaccine Sales Breakdown by Application (2016-2021)
6.3.2 North America Varicella Attenuated Live Vaccine Sales Breakdown by Application (2022-2027)
7 Europe Varicella Attenuated Live Vaccine Market Facts & Figures
7.1 Europe Varicella Attenuated Live Vaccine Sales by Company
7.1.1 Europe Varicella Attenuated Live Vaccine Sales by Company (2016-2021)
7.1.2 Europe Varicella Attenuated Live Vaccine Revenue by Company (2016-2021)
7.2 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Type
7.2.1 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Type (2016-2021)
7.2.2 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Type (2022-2027)
7.3 Europe Varicella Attenuated Live Vaccine Sales Breakdown by Application
7.3.1 Europe 130 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 130 Sales Breakdown by Application (2022-2027)
8 China Varicella Attenuated Live Vaccine Market Facts & Figures
8.1 China Varicella Attenuated Live Vaccine Sales by Company
8.1.1 China Varicella Attenuated Live Vaccine Sales by Company (2016-2021)
8.1.2 China Varicella Attenuated Live Vaccine Revenue by Company (2016-2021)
8.2 China Varicella Attenuated Live Vaccine Sales Breakdown by Type
8.2.1 China Varicella Attenuated Live Vaccine Sales Breakdown by Type (2016-2021)
8.2.2 China Varicella Attenuated Live Vaccine Sales Breakdown by Type (2022-2027)
8.3 China Varicella Attenuated Live Vaccine Sales Breakdown by Application
8.3.1 China 242 Sales Breakdown by Application (2016-2021)
8.3.2 China 242 Sales Breakdown by Application (2022-2027)
9 Japan Varicella Attenuated Live Vaccine Market Facts & Figures
9.1 Japan Varicella Attenuated Live Vaccine Sales by Company
9.1.1 Japan Varicella Attenuated Live Vaccine Sales by Company (2016-2021)
9.1.2 Japan Varicella Attenuated Live Vaccine Revenue by Company (2016-2021)
9.2 Japan Varicella Attenuated Live Vaccine Sales Breakdown by Type
9.2.1 Japan Varicella Attenuated Live Vaccine Sales Breakdown by Type (2016-2021)
9.2.2 Japan Varicella Attenuated Live Vaccine Sales Breakdown by Type (2022-2027)
9.3 Japan Varicella Attenuated Live Vaccine Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Varicella Attenuated Live Vaccine Market Facts & Figures
10.1 Southeast Asia Varicella Attenuated Live Vaccine Sales by Company
10.1.1 Southeast Asia Varicella Attenuated Live Vaccine Sales by Company (2016-2021)
10.1.2 Southeast Asia Varicella Attenuated Live Vaccine Revenue by Company (2016-2021)
10.2 Southeast Asia Varicella Attenuated Live Vaccine Sales Breakdown by Type
10.2.1 Southeast Asia Varicella Attenuated Live Vaccine Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Varicella Attenuated Live Vaccine Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Varicella Attenuated Live Vaccine Sales Breakdown by Application
10.3.1 Southeast Asia K Doses Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Doses Sales Breakdown by Application (2022-2027)
11 India Varicella Attenuated Live Vaccine Market Facts & Figures
11.1 India Varicella Attenuated Live Vaccine Sales by Company
11.1.1 India Varicella Attenuated Live Vaccine Sales by Company (2016-2021)
11.1.2 India Varicella Attenuated Live Vaccine Revenue by Company (2016-2021)
11.2 India Varicella Attenuated Live Vaccine Sales Breakdown by Type
11.2.1 India Varicella Attenuated Live Vaccine Sales Breakdown by Type (2016-2021)
11.2.2 India Varicella Attenuated Live Vaccine Sales Breakdown by Type (2022-2027)
11.3 India Varicella Attenuated Live Vaccine Sales Breakdown by Application
11.3.1 India Varicella Attenuated Live Vaccine Sales Breakdown by Application (2016-2021)
11.3.2 India Varicella Attenuated Live Vaccine Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Varicella Attenuated Live Vaccine Business
12.1 Merck
12.1.1 Merck Corporation Information
12.1.2 Merck Business Overview
12.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Merck Varicella Attenuated Live Vaccine Products Offered
12.1.5 Merck Recent Development
12.2 BCHT
12.2.1 BCHT Corporation Information
12.2.2 BCHT Business Overview
12.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.2.4 BCHT Varicella Attenuated Live Vaccine Products Offered
12.2.5 BCHT Recent Development
12.3 Shanghai Institute
12.3.1 Shanghai Institute Corporation Information
12.3.2 Shanghai Institute Business Overview
12.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Shanghai Institute Varicella Attenuated Live Vaccine Products Offered
12.3.5 Shanghai Institute Recent Development
12.4 GSK
12.4.1 GSK Corporation Information
12.4.2 GSK Business Overview
12.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.4.4 GSK Varicella Attenuated Live Vaccine Products Offered
12.4.5 GSK Recent Development
12.5 Keygen
12.5.1 Keygen Corporation Information
12.5.2 Keygen Business Overview
12.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Keygen Varicella Attenuated Live Vaccine Products Offered
12.5.5 Keygen Recent Development
12.6 Green Cross
12.6.1 Green Cross Corporation Information
12.6.2 Green Cross Business Overview
12.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Green Cross Varicella Attenuated Live Vaccine Products Offered
12.6.5 Green Cross Recent Development
12.7 Biken
12.7.1 Biken Corporation Information
12.7.2 Biken Business Overview
12.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Biken Varicella Attenuated Live Vaccine Products Offered
12.7.5 Biken Recent Development
12.8 Shanghai Rongsheng Biotech
12.8.1 Shanghai Rongsheng Biotech Corporation Information
12.8.2 Shanghai Rongsheng Biotech Business Overview
12.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Products Offered
12.8.5 Shanghai Rongsheng Biotech Recent Development
12.9 Changchun Changsheng Life Sciences Limited
12.9.1 Changchun Changsheng Life Sciences Limited Corporation Information
12.9.2 Changchun Changsheng Life Sciences Limited Business Overview
12.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Products Offered
12.9.5 Changchun Changsheng Life Sciences Limited Recent Development
13 Varicella Attenuated Live Vaccine Manufacturing Cost Analysis
13.1 Varicella Attenuated Live Vaccine Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
13.4 Varicella Attenuated Live Vaccine Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Varicella Attenuated Live Vaccine Distributors List
14.3 Varicella Attenuated Live Vaccine Customers
15 Market Dynamics
15.1 Varicella Attenuated Live Vaccine Market Trends
15.2 Varicella Attenuated Live Vaccine Drivers
15.3 Varicella Attenuated Live Vaccine Market Challenges
15.4 Varicella Attenuated Live Vaccine Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Varicella Attenuated Live Vaccine Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Varicella Attenuated Live Vaccine Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Varicella Attenuated Live Vaccine Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Region (2016-2021)
Table 5. Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2016-2021)
Table 6. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Varicella Attenuated Live Vaccine Revenue Share by Region (2016-2021)
Table 8. Global Varicella Attenuated Live Vaccine Sales (K Doses) Forecast by Region (2022-2027)
Table 9. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Varicella Attenuated Live Vaccine Revenue Share Forecast by Region (2022-2027)
Table 12. Global Varicella Attenuated Live Vaccine Sales (K Doses) of Key Companies (2016-2021)
Table 13. Global Varicella Attenuated Live Vaccine Sales Share by Company (2016-2021)
Table 14. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Varicella Attenuated Live Vaccine Revenue Share by Company (2016-2021)
Table 16. Global Varicella Attenuated Live Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Varicella Attenuated Live Vaccine as of 2020)
Table 17. Global Varicella Attenuated Live Vaccine Average Price (USD/Dose) of Key Company (2016-2021)
Table 18. Manufacturers Varicella Attenuated Live Vaccine Manufacturing Sites and Area Served
Table 19. Manufacturers Varicella Attenuated Live Vaccine Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Type (2016-2021)
Table 22. Global Varicella Attenuated Live Vaccine Sales Share by Type (2016-2021)
Table 23. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Type (2016-2021)
Table 25. Global Varicella Attenuated Live Vaccine Sales Share by Type (2022-2027)
Table 26. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Varicella Attenuated Live Vaccine Revenue Share by Type (2022-2027)
Table 28. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Type (2022-2027)
Table 29. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Application (2016-2021)
Table 30. Global Varicella Attenuated Live Vaccine Sales Share by Application (2016-2021)
Table 31. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Application (2016-2021)
Table 33. Global Varicella Attenuated Live Vaccine Sales (K Doses) by Application (2022-2027)
Table 34. Global Varicella Attenuated Live Vaccine Sales Share by Application (2022-2027)
Table 35. Global Varicella Attenuated Live Vaccine Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Varicella Attenuated Live Vaccine Revenue Share by Application (2022-2027)
Table 37. Global Varicella Attenuated Live Vaccine Price (USD/Dose) by Application (2022-2027)
Table 38. North America Varicella Attenuated Live Vaccine Sales (K Doses) by Company (2016-2021)
Table 39. North America Varicella Attenuated Live Vaccine Sales Market Share by Company (2016-2021)
Table 40. North America Varicella Attenuated Live Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Varicella Attenuated Live Vaccine Revenue Market Share by Company (2016-2021)
Table 42. North America Varicella Attenuated Live Vaccine Sales by Type (2016-2021) & (K Doses)
Table 43. North America Varicella Attenuated Live Vaccine Sales Market Share by Type (2016-2021)
Table 44. North America Varicella Attenuated Live Vaccine Sales by Type (2022-2027) & (K Doses)
Table 45. North America Varicella Attenuated Live Vaccine Sales Market Share by Type (2022-2027)
Table 46. North America Varicella Attenuated Live Vaccine Sales by Application (2016-2021) & (K Doses)
Table 47. North America Varicella Attenuated Live Vaccine Sales Market Share by Application (2016-2021)
Table 48. North America Varicella Attenuated Live Vaccine Sales by Application (2022-2027) & (K Doses)
Table 49. North America Varicella Attenuated Live Vaccine Sales Market Share by Application (2022-2027)
Table 50. Europe Varicella Attenuated Live Vaccine Sales (K Doses) by Company (2016-2021)
Table 51. Europe Varicella Attenuated Live Vaccine Sales Market Share by Company (2016-2021)
Table 52. Europe Varicella Attenuated Live Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Company (2016-2021)
Table 54. Europe Varicella Attenuated Live Vaccine Sales by Type (2016-2021) & (K Doses)
Table 55. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type (2016-2021)
Table 56. Europe Varicella Attenuated Live Vaccine Sales by Type (2022-2027) & (K Doses)
Table 57. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type (2022-2027)
Table 58. Europe Varicella Attenuated Live Vaccine Sales by Application (2016-2021) & (K Doses)
Table 59. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application (2016-2021)
Table 60. Europe Varicella Attenuated Live Vaccine Sales by Application (2022-2027) & (K Doses)
Table 61. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application (2022-2027)
Table 62. China Varicella Attenuated Live Vaccine Sales (K Doses) by Company (2016-2021)
Table 63. China Varicella Attenuated Live Vaccine Sales Market Share by Company (2016-2021)
Table 64. China Varicella Attenuated Live Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Varicella Attenuated Live Vaccine Revenue Market Share by Company (2016-2021)
Table 66. China Varicella Attenuated Live Vaccine Sales by Type (2016-2021) & (K Doses)
Table 67. China Varicella Attenuated Live Vaccine Sales Market Share by Type (2016-2021)
Table 68. China Varicella Attenuated Live Vaccine Sales by Type (2022-2027) & (K Doses)
Table 69. China Varicella Attenuated Live Vaccine Sales Market Share by Type (2022-2027)
Table 70. China Varicella Attenuated Live Vaccine Sales by Application (2016-2021) & (K Doses)
Table 71. China Varicella Attenuated Live Vaccine Sales Market Share by Application (2016-2021)
Table 72. China Varicella Attenuated Live Vaccine Sales by Application (2022-2027) & (K Doses)
Table 73. China Varicella Attenuated Live Vaccine Sales Market Share by Application (2022-2027)
Table 74. Japan Varicella Attenuated Live Vaccine Sales (K Doses) by Company (2016-2021)
Table 75. Japan Varicella Attenuated Live Vaccine Sales Market Share by Company (2016-2021)
Table 76. Japan Varicella Attenuated Live Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Varicella Attenuated Live Vaccine Revenue Market Share by Company (2016-2021)
Table 78. Japan Varicella Attenuated Live Vaccine Sales by Type (2016-2021) & (K Doses)
Table 79. Japan Varicella Attenuated Live Vaccine Sales Market Share by Type (2016-2021)
Table 80. Japan Varicella Attenuated Live Vaccine Sales by Type (2022-2027) & (K Doses)
Table 81. Japan Varicella Attenuated Live Vaccine Sales Market Share by Type (2022-2027)
Table 82. Japan Varicella Attenuated Live Vaccine Sales by Application (2016-2021) & (K Doses)
Table 83. Japan Varicella Attenuated Live Vaccine Sales Market Share by Application (2016-2021)
Table 84. Japan Varicella Attenuated Live Vaccine Sales by Application (2022-2027) & (K Doses)
Table 85. Japan Varicella Attenuated Live Vaccine Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Varicella Attenuated Live Vaccine Sales (K Doses) by Company (2016-2021)
Table 87. Southeast Asia Varicella Attenuated Live Vaccine Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Varicella Attenuated Live Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Varicella Attenuated Live Vaccine Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Varicella Attenuated Live Vaccine Sales by Type (2016-2021) & (K Doses)
Table 91. Southeast Asia Varicella Attenuated Live Vaccine Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Varicella Attenuated Live Vaccine Sales by Type (2022-2027) & (K Doses)
Table 93. Southeast Asia Varicella Attenuated Live Vaccine Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Varicella Attenuated Live Vaccine Sales by Application (2016-2021) & (K Doses)
Table 95. Southeast Asia Varicella Attenuated Live Vaccine Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Varicella Attenuated Live Vaccine Sales by Application (2022-2027) & (K Doses)
Table 97. Southeast Asia Varicella Attenuated Live Vaccine Sales Market Share by Application (2022-2027)
Table 98. India Varicella Attenuated Live Vaccine Sales (K Doses) by Company (2016-2021)
Table 99. India Varicella Attenuated Live Vaccine Sales Market Share by Company (2016-2021)
Table 100. India Varicella Attenuated Live Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Varicella Attenuated Live Vaccine Revenue Market Share by Company (2016-2021)
Table 102. India Varicella Attenuated Live Vaccine Sales by Type (2016-2021) & (K Doses)
Table 103. India Varicella Attenuated Live Vaccine Sales Market Share by Type (2016-2021)
Table 104. India Varicella Attenuated Live Vaccine Sales by Type (2022-2027) & (K Doses)
Table 105. India Varicella Attenuated Live Vaccine Sales Market Share by Type (2022-2027)
Table 106. India Varicella Attenuated Live Vaccine Sales by Application (2016-2021) & (K Doses)
Table 107. India Varicella Attenuated Live Vaccine Sales Market Share by Application (2016-2021)
Table 108. India Varicella Attenuated Live Vaccine Sales by Application (2022-2027) & (K Doses)
Table 109. India Varicella Attenuated Live Vaccine Sales Market Share by Application (2022-2027)
Table 110. Merck Corporation Information
Table 111. Merck Description and Business Overview
Table 112. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 113. Merck Varicella Attenuated Live Vaccine Product
Table 114. Merck Recent Development
Table 115. BCHT Corporation Information
Table 116. BCHT Description and Business Overview
Table 117. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 118. BCHT Varicella Attenuated Live Vaccine Product
Table 119. BCHT Recent Development
Table 120. Shanghai Institute Corporation Information
Table 121. Shanghai Institute Description and Business Overview
Table 122. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 123. Shanghai Institute Varicella Attenuated Live Vaccine Product
Table 124. Shanghai Institute Recent Development
Table 125. GSK Corporation Information
Table 126. GSK Description and Business Overview
Table 127. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 128. GSK Varicella Attenuated Live Vaccine Product
Table 129. GSK Recent Development
Table 130. Keygen Corporation Information
Table 131. Keygen Description and Business Overview
Table 132. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 133. Keygen Varicella Attenuated Live Vaccine Product
Table 134. Keygen Recent Development
Table 135. Green Cross Corporation Information
Table 136. Green Cross Description and Business Overview
Table 137. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 138. Green Cross Varicella Attenuated Live Vaccine Product
Table 139. Green Cross Recent Development
Table 140. Biken Corporation Information
Table 141. Biken Description and Business Overview
Table 142. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 143. Biken Varicella Attenuated Live Vaccine Product
Table 144. Biken Recent Development
Table 145. Shanghai Rongsheng Biotech Corporation Information
Table 146. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 147. Shanghai Rongsheng Biotech Description and Business Overview
Table 148. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product
Table 149. Shanghai Rongsheng Biotech Recent Development
Table 150. Changchun Changsheng Life Sciences Limited Corporation Information
Table 151. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 152. Changchun Changsheng Life Sciences Limited Description and Business Overview
Table 153. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product
Table 154. Changchun Changsheng Life Sciences Limited Recent Development
Table 155. Production Base and Market Concentration Rate of Raw Material
Table 156. Key Suppliers of Raw Materials
Table 157. Varicella Attenuated Live Vaccine Distributors List
Table 158. Varicella Attenuated Live Vaccine Customers List
Table 159. Varicella Attenuated Live Vaccine Market Trends
Table 160. Varicella Attenuated Live Vaccine Market Drivers
Table 161. Varicella Attenuated Live Vaccine Market Challenges
Table 162. Varicella Attenuated Live Vaccine Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Varicella Attenuated Live Vaccine Product Picture
Figure 2. Global Varicella Attenuated Live Vaccine Sales Market Share by Type in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Varicella Attenuated Live Vaccine Sales Market Share by Application in 2021 & 2027
Figure 6. Kids Injection Examples
Figure 7. Adults Injection Examples
Figure 8. Global Varicella Attenuated Live Vaccine Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 9. Global Varicella Attenuated Live Vaccine Sales Growth Rate (2016-2027) & (US$ Million)
Figure 10. Global Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2016-2027)
Figure 11. Global Varicella Attenuated Live Vaccine Price Trends Growth Rate (2016-2027) (USD/Dose)
Figure 12. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region: 2016 VS 2021
Figure 13. Global Varicella Attenuated Live Vaccine Revenue Market Share by Region: 2021 VS 2027
Figure 14. North America Varicella Attenuated Live Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 15. North America Varicella Attenuated Live Vaccine Sales (K Doses) Growth Rate (2016-2027)
Figure 16. Europe Varicella Attenuated Live Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 17. Europe Varicella Attenuated Live Vaccine Sales (Million USD) Growth Rate (2016-2027)
Figure 18. China Varicella Attenuated Live Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 19. China Varicella Attenuated Live Vaccine Sales (Million USD) and Growth Rate (2016-2027)
Figure 20. Japan Varicella Attenuated Live Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 21. Japan Varicella Attenuated Live Vaccine Sales (Million USD) Growth Rate (2016-2027)
Figure 22. Southeast Asia Varicella Attenuated Live Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 23. Southeast Asia Varicella Attenuated Live Vaccine Sales (Million USD) Growth Rate (2016-2027)
Figure 24. India Varicella Attenuated Live Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 25. India Varicella Attenuated Live Vaccine Sales (Million USD) Growth Rate (2016-2027)
Figure 26. Global 5 Largest Varicella Attenuated Live Vaccine Players Market Share by Revenue in Varicella Attenuated Live Vaccine: 2016 & 2020
Figure 27. Varicella Attenuated Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 28. Global Varicella Attenuated Live Vaccine Revenue Share by Type (2016-2021)
Figure 29. Global Varicella Attenuated Live Vaccine Revenue Growth Rate by Type in 2016 & 2020
Figure 30. Global Varicella Attenuated Live Vaccine Revenue Share by Application (2016-2021)
Figure 31. Global Varicella Attenuated Live Vaccine Revenue Growth Rate by Application in 2016 & 2020
Figure 32. North America Varicella Attenuated Live Vaccine Sales Market Share by Type in 2020
Figure 33. North America Varicella Attenuated Live Vaccine Sales Market Share by Application in 2020
Figure 34. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type in 2020
Figure 35. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application in 2020
Figure 36. China Varicella Attenuated Live Vaccine Sales Market Share by Type in 2020
Figure 37. China Varicella Attenuated Live Vaccine Sales Market Share by Application in 2020
Figure 38. Japan Varicella Attenuated Live Vaccine Sales Market Share by Type in 2020
Figure 39. Japan Varicella Attenuated Live Vaccine Sales Market Share by Application in 2020
Figure 40. Southeast Asia Varicella Attenuated Live Vaccine Sales Market Share by Type in 2020
Figure 41. Southeast Asia Varicella Attenuated Live Vaccine Sales Market Share by Application in 2020
Figure 42. India Varicella Attenuated Live Vaccine Sales Market Share by Type in 2020
Figure 43. India Varicella Attenuated Live Vaccine Sales Market Share by Application in 2020
Figure 44. Key Raw Materials Price Trend
Figure 45. Manufacturing Cost Structure of Varicella Attenuated Live Vaccine
Figure 46. Manufacturing Process Analysis of Varicella Attenuated Live Vaccine
Figure 47. Varicella Attenuated Live Vaccine Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
水痘ウイルス生ワクチンのグローバル市場調査 2019年 The global Varicella Virus Vaccine Live market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Varicella Virus Vaccine Live volume and value at global level, regional level and company level. From a global…- 水痘ウイルス生ワクチンのグローバル市場調査 2019年 The global Varicella Virus Vaccine Live market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Varicella Virus Vaccine Live volume and value at global level, regional level and company level. From a global…
- 水痘ウイルス(水痘)ワクチンのグローバル市場調査 2019年 The global Varicella Virus (Chickenpox) Vaccine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Varicella Virus (Chickenpox) Vaccine volume and value at global level, regional level and company leve…
- 水痘ウイルス(水痘)ワクチンのグローバル市場調査 2019年 The global Varicella Virus (Chickenpox) Vaccine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Varicella Virus (Chickenpox) Vaccine volume and value at global level, regional level and company leve…
- 水痘ウイルスワクチンのグローバル市場調査 2019年 The global Varicella Virus Vaccine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Varicella Virus Vaccine volume and value at global level, regional level and company level. From a global perspecti…